经肠营养市场－全球产业规模、份额、趋势、机会及预测（依产品、流型、阶段、适应症、最终用途、地区及竞争格局划分，2021-2031年）

全球经肠营养市场预计将从 2025 年的 68.5 亿美元成长到 2031 年的 99.7 亿美元，复合年增长率为 6.46%。

这些营养配方是专为难以口服营养的患者设计的特殊液体营养製剂，透过导管直接输送到消化道。市场成长的驱动因素包括全球慢性病负担日益加重以及人口快速老化，这些因素都需要持续的营养支持。此外，居家医疗保健的趋势也加速了市场需求，因为它提供了比长期住院治疗更经济有效的替代方案。国际医疗营养产业协会强调了临床营养干预的迫切性，指出到2025年，欧洲将有3,300万人营养不良或面临营养不良的风险。

然而，各地区复杂的健保报销环境严重阻碍了市场扩张。保险覆盖范围的不统一，尤其是在居家照护中使用的配方奶粉，造成了经济障碍，限制了许多患者的获取途径和负担能力。这些经济限制可能会阻碍患者及时开始必要的营养治疗，尤其是在价格敏感型经济体中，自付费用是主要考虑因素，从而限制了整体市场成长。

市场驱动因素

全球慢性疾病（尤其是胃肠道疾病和癌症）盛行率的不断上升，是推动经肠营养市场成长的主要因素。长期患病的患者往往营养不良严重，吞嚥功能受损，需要临床营养介入以维持生理稳定。恶性肿瘤发生率的不断上升，以及化疗等积极治疗手段的增多，进一步刺激了这项需求。这些治疗通常会阻碍患者经口进食，需要管饲才能復原。根据美国癌症协会于2025年1月发布的《2025年癌症事实与数据》报告，预计仅在美国就将新增2,041,910例癌症病例，凸显了需要营养支持的患者群体不断扩大。

随着疾病负担的日益加重，针对特定疾病的个人化配方应运而生，进一步推动了市场发展，满足个体代谢需求。製造商正在研发针对糖尿病、肾衰竭和吸收不良等疾病的营养配方，与标准聚合物配方相比，这些配方能够改善临床疗效并提高患者耐受性。这种对个人化营养的关注正在推动主要企业营收成长。例如，达能公司在2025年2月发布的「2024财年全年业绩报告」中，其特种营养品部门的销售额成长了4.6%。同样，费森尤斯公司在2025年公布的营养品业务部门2024财年销售额增长了4%，总额达到24亿欧元，反映出整个行业的强劲增长势头。

市场挑战

全球经肠营养市场面临的主要经济障碍之一是复杂的报销体系。严格的资格标准和不一致的区域保险政策给看护者和患者带来了沉重的经济负担，尤其是在不断发展的居家医疗领域。当第三方支付方对这些重要的营养製剂的报销不足或拒付时，由此产生的高额自付费用往往会阻碍患者开始或继续必要的长期治疗。这种经济摩擦直接限制了产品的使用，并抑制了收入潜力，尤其是在价格敏感型经济体中。

此外，报销相关的行政负担也使得医疗机构难以维持充足的特殊营养配方库存。 2025年，美国肠内肠外营养学会指出，由于某些监管调整措施的到期，许多居家医疗设备供应商的报销率下降了30%以上，严重影响了其提供经肠营养资源的运作能力。这种财务上的不稳定性迫使医疗机构缩减服务范围，从而限制了患者的就医途径，并直接阻碍了市场的整体成长。

市场趋势

製造商正越来越多地将免疫调节营养素（例如核苷酸、精氨酸和Omega-3脂肪酸）添加到旨在支持术前和重症监护患者康復的配方中。这种对代谢支持和免疫营养的关注旨在应对重症监护患者所经历的急性生理应激，这与通常推动需求的慢性病管理领域截然不同。这种对高度急性照护的策略性关注正在推动市场领导取得强劲的财务表现。例如，费森尤斯卡比公司于2025年3月发布的2024年度报告显示，其临床营养业务部门实现了13%的有机销售成长，这主要得益于其在重症监护领域地位的提升。

与临床配方技术的进步相呼应的是，配方正发生显着变化，不再仅依赖合成营养素，而是更多地采用肉类、蔬菜和水果等全食物成分。这种朝向「真食物」和搅拌机加工解决方案的转变，源自于消费者对「洁净标示」产品的需求。这些产品模拟天然饮食，据报导有助于改善长期使用者的心理健康和肠胃耐受性。这一趋势的商业性影响显而易见。雀巢健康科学在其2024年11月的「资本市场日」活动中透露，其医疗营养业务在全球范围内实现了两位数的增长，这在很大程度上得益于其植物来源和「真食物」产品线的强劲市场表现。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球经肠营养市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（标准配方、疾病特异性配方）
  • 依流量类型（间歇性营养供应流量、连续性营养供应流量）
  • 依阶段（成人、儿童）
  • 根据适应症（阿兹海默症、营养缺乏、癌症治疗、糖尿病、慢性肾臟病、罕见疾病、吞嚥障碍、疼痛管理、吸收不良/胃肠道疾病/腹泻、其他）
  • 按用途（医院、居家医疗）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美经肠营养市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲经肠营养市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区经肠营养市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲经肠营养市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美经肠营养市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球经肠营养市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abbott Laboratories Inc
• Danone SA
• Fresenius Kabi AG
• Nestle SA
• VICTUS Inc.
• Primus Pharmaceuticals, Inc.
• Meiji Holdings. Co Ltd.
• Mead Johnson & Company, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Enteral Feeding Formulas Market is projected to expand from USD 6.85 Billion in 2025 to USD 9.97 Billion by 2031, registering a CAGR of 6.46%. These formulas consist of specialized liquid nutritional compositions administered directly into the gastrointestinal tract via a tube, designed for patients who cannot consume food orally. The market's growth is driven by the increasing global burden of chronic diseases and a rapidly aging population that necessitates consistent nutritional support. Furthermore, the trend toward home-based healthcare is accelerating demand by offering a cost-effective alternative to extended hospital stays. Underscoring the urgency for clinical nutrition interventions, the Medical Nutrition International Industry highlighted in 2025 that 33 million individuals in Europe were either malnourished or at risk of malnutrition.

However, market expansion is significantly hindered by a complex reimbursement landscape across various regions. Inconsistent insurance coverage, particularly for formulas used in home care settings, creates financial obstacles that limit accessibility and affordability for many patients. These economic constraints can impede the timely initiation of essential nutritional therapy and restrict overall market growth, especially in price-sensitive economies where out-of-pocket costs are a major concern.

Market Driver

The rising global prevalence of chronic diseases, specifically gastrointestinal disorders and cancer, acts as a major catalyst for the growth of the enteral feeding formulas market. Patients dealing with these long-term conditions often face severe malnutrition or compromised swallowing abilities, requiring clinical nutritional interventions to maintain physiological stability. This demand is further intensified by the increasing incidence of malignancies necessitating aggressive treatments like chemotherapy, which often impair oral intake and mandate tube feeding for recovery. The American Cancer Society's 'Cancer Facts & Figures 2025' report, released in January 2025, projected 2,041,910 new cancer diagnoses in the United States alone, highlighting the expanding patient pool in need of supportive nutritional care.

Alongside rising disease burdens, the market is bolstered by advancements in personalized and disease-specific formulas tailored to meet unique metabolic needs. Manufacturers are developing specialized compositions for conditions like diabetes, renal failure, and malabsorption, which offer improved clinical outcomes and patient tolerance compared to standard polymeric feeds. This focus on tailored nutrition has driven revenue growth for key players; for example, Danone reported in its 'Full Year 2024 Results' in February 2025 that sales in its Specialized Nutrition division rose by 4.6%. Similarly, Fresenius reported in 2025 that its Nutrition business segment achieved a revenue increase of 4%, totaling €2.4 billion for the fiscal year 2024, reflecting strong sector-wide momentum.

Market Challenge

A primary economic barrier impeding the Global Enteral Feeding Formulas Market is the complex reimbursement landscape. Restrictive coverage criteria and inconsistent insurance policies across different regions create substantial financial liabilities for caregivers and patients, especially within the expanding home care sector. When third-party payers provide inadequate funding or deny claims for these vital nutritional compositions, the resulting high out-of-pocket costs frequently discourage patients from starting or continuing necessary long-term therapy. This economic friction directly limits product utilization volume and stifles revenue potential, particularly in economies where price sensitivity is high.

Additionally, the administrative burden involved in securing reimbursement deters suppliers from keeping robust inventories of specialized formulas. In 2025, the American Society for Parenteral and Enteral Nutrition noted that the expiration of specific regulatory adjustments led to reimbursement rate cuts of over 30% for many home medical equipment suppliers, severely straining their operational capacity to provide enteral nutrition resources. Such financial instability compels providers to limit their service offerings, thereby restricting patient access and directly hampering the market's overall growth trajectory.

Market Trends

Manufacturers are increasingly integrating immune-modulating nutrients, such as nucleotides, arginine, and omega-3 fatty acids, into formulations aimed at supporting recovery in pre-operative and critical care environments. This emphasis on metabolic support and immunonutrition addresses the acute physiological stress experienced by intensive care patients, a segment distinct from the chronic disease management that typically drives volume. This strategic focus on high-acuity therapies has resulted in strong financial performance for market leaders; for example, Fresenius Kabi's 'Annual Report 2024', published in March 2025, reported that its Clinical Nutrition business segment achieved a 13% organic revenue increase, driven by its strengthening position in critical care therapies.

Parallel to the advancement of clinical formulations, there is a significant shift toward formulas containing whole-food ingredients like meats, vegetables, and fruits, rather than relying solely on synthetic nutrients. This movement toward "real food" and blenderized solutions is fueled by the demand for "clean label" products that mimic a natural diet, which reportedly enhances psychological well-being and gastrointestinal tolerance for long-term users. The commercial impact of this trend is evident; Nestle Health Science revealed in its November 2024 'Capital Markets Day' presentation that its Medical Nutrition business achieved double-digit growth globally, significantly propelled by the robust adoption of its plant-based and "real food" product lines.

Key Market Players

• Abbott Laboratories Inc
• Danone S.A
• Fresenius Kabi AG
• Nestle S.A.
• VICTUS Inc.
• Primus Pharmaceuticals, Inc.
• Meiji Holdings. Co Ltd.
• Mead Johnson & Company, LLC

Report Scope

In this report, the Global Enteral Feeding Formulas Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Enteral Feeding Formulas Market, By Product

• Standard Formula
• Disease-specific Formulas

Enteral Feeding Formulas Market, By Flow Type

• Intermittent Feeding Flow
• Continuous Feeding Flow

Enteral Feeding Formulas Market, By Stage

• Adults
• Pediatrics

Enteral Feeding Formulas Market, By Indication

• Alzheimer's
• Nutrition Deficiency
• Cancer Care
• Diabetes
• Chronic Kidney Diseases
• Orphan Diseases
• Dysphagia
• Pain Management
• Malabsorption/GI Disorder/Diarrhea
• Others

Enteral Feeding Formulas Market, By End-Use

• Hospitals
• Homecare

Enteral Feeding Formulas Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Enteral Feeding Formulas Market.

Available Customizations:

Global Enteral Feeding Formulas Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Enteral Feeding Formulas Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Standard Formula, Disease-specific Formulas)
  • 5.2.2. By Flow Type (Intermittent Feeding Flow, Continuous Feeding Flow)
  • 5.2.3. By Stage (Adults, Pediatrics)
  • 5.2.4. By Indication (Alzheimer's, Nutrition Deficiency, Cancer Care, Diabetes, Chronic Kidney Diseases, Orphan Diseases, Dysphagia, Pain Management, Malabsorption/GI Disorder/Diarrhea, Others)
  • 5.2.5. By End-Use (Hospitals, Homecare)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Enteral Feeding Formulas Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Flow Type
  • 6.2.3. By Stage
  • 6.2.4. By Indication
  • 6.2.5. By End-Use
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Enteral Feeding Formulas Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Flow Type
      • 6.3.1.2.3. By Stage
      • 6.3.1.2.4. By Indication
      • 6.3.1.2.5. By End-Use
  • 6.3.2. Canada Enteral Feeding Formulas Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Flow Type
      • 6.3.2.2.3. By Stage
      • 6.3.2.2.4. By Indication
      • 6.3.2.2.5. By End-Use
  • 6.3.3. Mexico Enteral Feeding Formulas Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Flow Type
      • 6.3.3.2.3. By Stage
      • 6.3.3.2.4. By Indication
      • 6.3.3.2.5. By End-Use

7. Europe Enteral Feeding Formulas Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Flow Type
  • 7.2.3. By Stage
  • 7.2.4. By Indication
  • 7.2.5. By End-Use
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Enteral Feeding Formulas Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Flow Type
      • 7.3.1.2.3. By Stage
      • 7.3.1.2.4. By Indication
      • 7.3.1.2.5. By End-Use
  • 7.3.2. France Enteral Feeding Formulas Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Flow Type
      • 7.3.2.2.3. By Stage
      • 7.3.2.2.4. By Indication
      • 7.3.2.2.5. By End-Use
  • 7.3.3. United Kingdom Enteral Feeding Formulas Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Flow Type
      • 7.3.3.2.3. By Stage
      • 7.3.3.2.4. By Indication
      • 7.3.3.2.5. By End-Use
  • 7.3.4. Italy Enteral Feeding Formulas Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Flow Type
      • 7.3.4.2.3. By Stage
      • 7.3.4.2.4. By Indication
      • 7.3.4.2.5. By End-Use
  • 7.3.5. Spain Enteral Feeding Formulas Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Flow Type
      • 7.3.5.2.3. By Stage
      • 7.3.5.2.4. By Indication
      • 7.3.5.2.5. By End-Use

8. Asia Pacific Enteral Feeding Formulas Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Flow Type
  • 8.2.3. By Stage
  • 8.2.4. By Indication
  • 8.2.5. By End-Use
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Enteral Feeding Formulas Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Flow Type
      • 8.3.1.2.3. By Stage
      • 8.3.1.2.4. By Indication
      • 8.3.1.2.5. By End-Use
  • 8.3.2. India Enteral Feeding Formulas Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Flow Type
      • 8.3.2.2.3. By Stage
      • 8.3.2.2.4. By Indication
      • 8.3.2.2.5. By End-Use
  • 8.3.3. Japan Enteral Feeding Formulas Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Flow Type
      • 8.3.3.2.3. By Stage
      • 8.3.3.2.4. By Indication
      • 8.3.3.2.5. By End-Use
  • 8.3.4. South Korea Enteral Feeding Formulas Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Flow Type
      • 8.3.4.2.3. By Stage
      • 8.3.4.2.4. By Indication
      • 8.3.4.2.5. By End-Use
  • 8.3.5. Australia Enteral Feeding Formulas Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Flow Type
      • 8.3.5.2.3. By Stage
      • 8.3.5.2.4. By Indication
      • 8.3.5.2.5. By End-Use

9. Middle East & Africa Enteral Feeding Formulas Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Flow Type
  • 9.2.3. By Stage
  • 9.2.4. By Indication
  • 9.2.5. By End-Use
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Enteral Feeding Formulas Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Flow Type
      • 9.3.1.2.3. By Stage
      • 9.3.1.2.4. By Indication
      • 9.3.1.2.5. By End-Use
  • 9.3.2. UAE Enteral Feeding Formulas Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Flow Type
      • 9.3.2.2.3. By Stage
      • 9.3.2.2.4. By Indication
      • 9.3.2.2.5. By End-Use
  • 9.3.3. South Africa Enteral Feeding Formulas Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Flow Type
      • 9.3.3.2.3. By Stage
      • 9.3.3.2.4. By Indication
      • 9.3.3.2.5. By End-Use

10. South America Enteral Feeding Formulas Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Flow Type
  • 10.2.3. By Stage
  • 10.2.4. By Indication
  • 10.2.5. By End-Use
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Enteral Feeding Formulas Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Flow Type
      • 10.3.1.2.3. By Stage
      • 10.3.1.2.4. By Indication
      • 10.3.1.2.5. By End-Use
  • 10.3.2. Colombia Enteral Feeding Formulas Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Flow Type
      • 10.3.2.2.3. By Stage
      • 10.3.2.2.4. By Indication
      • 10.3.2.2.5. By End-Use
  • 10.3.3. Argentina Enteral Feeding Formulas Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Flow Type
      • 10.3.3.2.3. By Stage
      • 10.3.3.2.4. By Indication
      • 10.3.3.2.5. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Enteral Feeding Formulas Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Danone S.A
• 15.3. Fresenius Kabi AG
• 15.4. Nestle S.A.
• 15.5. VICTUS Inc.
• 15.6. Primus Pharmaceuticals, Inc.
• 15.7. Meiji Holdings. Co Ltd.
• 15.8. Mead Johnson & Company, LLC

16. Strategic Recommendations

17. About Us & Disclaimer